NEW YORK (GenomeWeb News) – DiscoveRx said today that it will provide GlaxoSmithKline with cell lines and reagents for G-protein coupled receptor screening.
Under the worldwide pact, DiscoveRx, based in Fremont, Calif., will provide GSK with access to its PathHunter beta-arresting parental cell lines, clones, and associated reagents for use in GSK's internal GPCR screening and profiling efforts.
Financial terms of the agreement were not disclosed.
DiscoveRx said that the agreement follows in the wake of a collaborative GPCR orphan receptor program that included GSK, DiscoveRx, and the UK's Medical Research Council.